Maravai LifeSciences Holdings, Inc. (MRVI) Financial Ratios
8 years of historical data (2018–2025) · Healthcare · Biotechnology
EV/EBITDA
↑
N/A
—
5yr avg: 21.47
30Y Low3.0·High52.5
P/FCF
↓
N/A
—
5yr avg: 10.77
30Y Low3.6·High21.4
P/B Ratio
↓
1.53
↓-49% vs avg
5yr avg: 3.02
30Y Low1.1·High17.5
ROE
↓
-27.5%
↑-803% vs avg
5yr avg: 3.9%
30Y Low-28%·High52%
Debt/EBITDA
↑
N/A
—
5yr avg: 12.54
30Y Low1.0·High35.7
Percentile shows where the current value sits in 30-year historical distribution. Sparklines show 5-year trend.
MRVI Valuation Multiples
Price-based multiples — how expensive the stock is relative to earnings, sales, book value, and cash flow
Maravai LifeSciences Holdings, Inc. currently has a negative P/E ratio, indicating the company is operating at a loss on a trailing-twelve-month basis.
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 |
|---|---|---|---|---|---|---|---|---|---|
| Market Cap | $436M | $471M | $752M | $864M | $1.9B | $5.1B | $2.7B | — | — |
| Enterprise Value | $255M | $290M | $806M | $900M | $1.8B | $5.1B | $3.1B | — | — |
| P/E Ratio → | -16.42 | — | — | — | 8.57 | 26.86 | 11.89 | — | — |
| P/S Ratio | 8.75 | 9.46 | 2.90 | 2.99 | 2.13 | 6.39 | 9.54 | — | — |
| P/B Ratio | 1.53 | 1.27 | 1.30 | 1.09 | 2.08 | 9.37 | 17.52 | — | — |
| P/FCF | — | — | — | 14.24 | 3.63 | 14.45 | 21.38 | — | — |
| P/OCF | — | — | 100.68 | 6.85 | 3.52 | 13.87 | 17.81 | — | — |
P/E links to full P/E history page with 30-year chart
MRVI EV Ratios
Enterprise-value multiples — capital-structure-neutral measures of total business value
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 |
|---|---|---|---|---|---|---|---|---|---|
| EV / Revenue | — | 5.82 | 3.11 | 3.12 | 2.08 | 6.42 | 10.79 | — | — |
| EV / EBITDA | — | — | — | 52.53 | 3.00 | 8.86 | 21.03 | — | — |
| EV / EBIT | — | — | — | 1.36 | 3.21 | 9.15 | 27.26 | — | — |
| EV / FCF | — | — | — | 14.84 | 3.54 | 14.52 | 24.18 | — | — |
MRVI Profitability
Margins and return-on-capital ratios measuring operating efficiency
Maravai LifeSciences Holdings, Inc. earns an operating margin of -431.7%. Operating margins have compressed from -11.0% to -431.7% over the past 3 years, signaling potential cost pressures or competitive headwinds. A negative ROE of -27.5% indicates the company is currently destroying shareholder equity.
Margins
Full margin charts and quarterly trend are on the Earnings History page
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 |
|---|---|---|---|---|---|---|---|---|---|
| Gross Margin | 25.8% | 25.8% | 41.8% | 48.5% | 80.9% | 82.4% | 72.0% | 53.3% | 50.9% |
| Operating Margin | -431.7% | -431.7% | -90.9% | -11.0% | 65.0% | 69.4% | 42.2% | 16.8% | 13.3% |
| Net Profit Margin | -262.2% | -262.2% | -55.9% | -41.2% | 24.9% | 22.8% | 27.1% | -5.9% | -14.3% |
Return on Capital
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 |
|---|---|---|---|---|---|---|---|---|---|
| ROE | -27.5% | -27.5% | -21.2% | -14.0% | 30.4% | 52.0% | 51.4% | -5.8% | -12.0% |
| ROA | -14.7% | -14.7% | -11.6% | -6.3% | 10.5% | 11.4% | 8.3% | -1.5% | -3.3% |
| ROIC | -39.2% | -39.2% | -24.3% | -2.8% | 60.3% | 77.1% | 17.6% | 3.7% | 2.6% |
| ROCE | -25.7% | -25.7% | -20.0% | -1.8% | 28.7% | 37.4% | 14.2% | 4.6% | 3.3% |
MRVI Leverage & Debt
Solvency and debt-coverage ratios — lower is generally safer
The company holds a net cash position — cash of $217M exceeds total debt of $36M, providing substantial financial flexibility for buybacks, acquisitions, or weathering downturns.
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 |
|---|---|---|---|---|---|---|---|---|---|
| Debt / Equity | 0.10 | 0.10 | 0.65 | 0.77 | 0.65 | 1.05 | 3.82 | 2.70 | 2.30 |
| Debt / EBITDA | — | — | — | 35.66 | 0.96 | 0.99 | 4.05 | 8.12 | 8.76 |
| Net Debt / Equity | — | -0.49 | 0.09 | 0.05 | -0.05 | 0.04 | 2.29 | 2.53 | 2.15 |
| Net Debt / EBITDA | — | — | — | 2.10 | -0.08 | 0.04 | 2.43 | 7.60 | 8.20 |
| Debt / FCF | — | — | — | 0.59 | -0.09 | 0.07 | 2.80 | 52.46 | — |
| Interest Coverage | — | — | -4.94 | -0.69 | 28.13 | 18.33 | 3.90 | 0.80 | 0.60 |
Net cash position: cash ($217M) exceeds total debt ($36M)
MRVI Liquidity & Efficiency
Short-term solvency ratios and asset-utilisation metrics
Maravai LifeSciences Holdings, Inc.'s current ratio of 6.60x is well above the 1.0 safety threshold, indicating strong short-term liquidity with ample room to cover current liabilities. The quick ratio of 5.69x is notably lower than the current ratio, indicating a significant portion of current assets is tied up in inventory. The current ratio has declined from 8.00x to 6.60x over the past 3 years.
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 |
|---|---|---|---|---|---|---|---|---|---|
| Current Ratio | 6.60 | 6.60 | 7.53 | 8.00 | 7.70 | 7.89 | 2.54 | 2.05 | 1.50 |
| Quick Ratio | 5.69 | 5.69 | 6.65 | 7.41 | 7.31 | 7.34 | 2.28 | 1.57 | 1.10 |
| Cash Ratio | 4.83 | 4.83 | 5.66 | 6.57 | 5.74 | 5.88 | 1.81 | 0.84 | 0.61 |
| Asset Turnover | — | 0.06 | 0.26 | 0.19 | 0.39 | 0.42 | 0.22 | 0.25 | 0.23 |
| Inventory Turnover | 0.91 | 0.91 | 3.01 | 2.89 | 3.92 | 2.73 | 2.39 | 4.71 | 4.25 |
| Days Sales Outstanding | — | 186.64 | 54.25 | 70.39 | 60.69 | 53.67 | 65.55 | 45.98 | 47.13 |
MRVI Shareholder Yields
Earnings, FCF, buyback, and dividend yields — total returns to shareholders
Maravai LifeSciences Holdings, Inc. does not currently pay a dividend and has no material buyback yield, reinvesting earnings back into the business.
Dividends
Full dividend history and growth charts are on the Dividend History page
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 |
|---|---|---|---|---|---|---|---|---|---|
| Dividend Yield | — | — | — | — | — | — | — | — | — |
| Payout Ratio | — | — | — | — | — | — | — | — | — |
Total Shareholder Return Metrics
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 |
|---|---|---|---|---|---|---|---|---|---|
| Earnings Yield | — | — | — | — | 11.7% | 3.7% | 8.4% | — | — |
| FCF Yield | — | — | — | 7.0% | 27.5% | 6.9% | 4.7% | — | — |
| Buyback Yield | 0.0% | 0.0% | 0.3% | 0.0% | 0.0% | 0.0% | 53.8% | — | — |
| Total Shareholder Yield | 0.0% | 0.0% | 0.3% | 0.0% | 0.0% | 0.0% | 53.8% | — | — |
| Shares Outstanding | — | $145M | $138M | $132M | $132M | $122M | $97M | $97M | $89M |
Peer Comparison
Compare MRVI with 10 similar companies in its peer group
| Company | Market Cap | P/E | EV/EBITDA | P/FCF | Gross Margin | Op Margin | ROE | ROIC | Debt/EBITDA |
|---|---|---|---|---|---|---|---|---|---|
 MRVIYou | $436M | -16.4 | — | — | 25.8% | -431.7% | -27.5% | -39.2% | — |
 AZTA | $855M | -15.2 | 13.8 | 22.3 | 45.5% | -1.9% | -3.2% | -0.5% | 2.2 |
 NUVL | $8B | -17.5 | — | — | — | — | -36.7% | -32.5% | — |
 BCAB | $5M | -0.1 | — | — | 100.0% | -2965.3% | — | — | — |
 ALNY | $39B | 127.0 | 70.2 | 84.8 | 81.8% | 13.5% | 73.3% | 33.4% | 2.3 |
 ILMN | $21B | 25.5 | 19.6 | 22.6 | 66.7% | 19.9% | 33.4% | 16.8% | 2.3 |
 PACB | $498M | -0.9 | — | — | 31.7% | -348.5% | -213.5% | -45.8% | — |
 TWST | $4B | -45.0 | — | — | 50.7% | -36.2% | -16.4% | -26.9% | — |
 BEAM | $3B | -38.9 | — | — | 84.0% | -274.6% | -8.1% | -31.1% | — |
 NTLA | $2B | -3.6 | — | — | 76.5% | -651.7% | -53.5% | -44.0% | — |
 CRSP | $5B | -8.1 | — | — | -6537.0% | -16191.4% | -30.2% | -22.3% | — |
| Healthcare Median | — | 22.3 | 14.4 | 18.5 | 63.9% | -5.2% | -33.7% | -11.2% | 3.3 |
Peer selection based on competitive and market overlap. Compare multiple stocks →
Download Financial Ratios Data
Includes 30+ ratios · 8 years · Updated daily
See MRVI's True Return
Price is only half the story. See total return with reinvested dividends.
Launch CalculatorIs MRVI Undervalued?
DCF intrinsic value, peer multiples, and analyst estimates — see what the stock is really worth.
View ValuationCompare MRVI vs AZTA
Side-by-side business, growth, and profitability comparison vs Azenta, Inc..
Start ComparisonMRVI — Frequently Asked Questions
Quick answers to the most common questions about buying MRVI stock.
What is Maravai LifeSciences Holdings, Inc.'s P/E ratio?
Maravai LifeSciences Holdings, Inc.'s current P/E ratio is -16.4x. The historical average is 15.8x.
What is Maravai LifeSciences Holdings, Inc.'s ROE?
Maravai LifeSciences Holdings, Inc.'s return on equity (ROE) is -27.5%. The historical average is 6.6%.
Is MRVI stock overvalued?
Based on historical data, Maravai LifeSciences Holdings, Inc. is trading at a P/E of -16.4x. Compare with industry peers and growth rates for a complete picture.
What are Maravai LifeSciences Holdings, Inc.'s profit margins?
Maravai LifeSciences Holdings, Inc. has 25.8% gross margin and -431.7% operating margin.